Pharmaceutical - Financial, Mergers & Acquisitions

Filter

Popular Filters

1 to 25 of 7389 results

Marken ready for orphan drug distribution

24-04-2014

USA-based Marken, a global clinical supply chain solutions provider, has released a new white paper which…

Markets & MarketingPharmaceuticalProductionRare diseases

WuXi PharmaTech announces Management Appointments

WuXi PharmaTech announces Management Appointments

24-04-2014

China’s WuXi PharmaTech (NYSE: WX) has announced that Dr Steve Yang has joined the company as Executive…

BiotechnologyBoardroomChinaPharmaceuticalWuXi PharmaTech

AstraZeneca first quarter sales flat, but beat forecasts

24-04-2014

Anglo-Swedish drug major AstraZeneca this morning posted first-quarter 2014 financials, revealed sales…

AstraZenecaFinancialPharmaceutical

Eli Lilly 1st-qtr 2014 net income plunges, sales down, hit by generic competition

24-04-2014

US pharma major Eli Lilly posted first-quarter 2014 financial results, with revenue declined 16 % to…

Eli LillyFinancialPharmaceutical

Hyperion Therapeutics to broaden orphan disease pipeline with buy of Israeli firm

24-04-2014

US biotech firm Hyperion Therapeutics has entered into a definitive agreement to acquire Andromeda Biotech,…

Andromeda BiotechBiotechnologyDiabetesDiaPep277Hyperion TherapeuticsMergers & Acquisitions

Merck releases positive Ph IIIb results for Kuvan

24-04-2014

German pharma and life sciences major Merck KGaA announced today that the Phase IIIb SPARK study with…

KuvanMerck KGaAPharmaceuticalRare diseasesResearch

Impax Laboratories appoints Frederick Wilkinson as President and CEO

Impax Laboratories appoints Frederick Wilkinson as President and CEO

24-04-2014

US generic drugmaker Impax Laboratories (NASDAQ: IPXL) has announced the appointment of Frederick Wilkinson…

BiotechnologyBoardroomImpax LaboratoriesPharmaceuticalUSA

FDA backs Janssen’s Sylvant for rare disease

24-04-2014

The US Food and Drug Administration yesterday approved Johnson & Johnson subsidiary Janssen Biotech’s…

Janssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRare diseasesRegulationsiltuximabSylvantUSA

Novartis 1st-qtr net profit flat, sales shy of forecasts

Novartis 1st-qtr net profit flat, sales shy of forecasts

24-04-2014

Swiss drug major Novartis posted a solid set of first-quarter 2014 financials this morning, showing that…

AlconFinancialNovartisPharmaceuticalSandoz

Biogen Idec 1st-qtr 2014 revenue leaps 51%, driven by Tecfidera and MS franchise

23-04-2014

US biotech firm Biogen Idec first-quarter 2014 results today, including revenue of $2.1 billion, a 51%…

Biogen IdecBiotechnologyFinancialNeurologicalResearchTecfidera

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

Abbott may acquire one of Russia’s leading drugmakers for $240 million

23-04-2014

The USA’s Abbott Laboratories is considering acquiring the 81.1 % stake in Veropharm, one of Russia’s…

Abbott LaboratoriesGenericsMergers & AcquisitionsRussiaVeropharm

Allergan adopts stockholder rights plan

23-04-2014

USA-based Allergan, the subject of a hostile takeover bid from Canada’s Valeant Pharmaceuticals reported…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Amgen's 1st-qtr 2014 disappoints, as net income falls 25%

23-04-2014

Amgen, the world’s largest independent biotech firm by revenues, yesterday announced financial results…

AmgenBiotechnologyFinancialResearch

Pharmaceutical CPI growth due to Australian government policy

23-04-2014

The Australian Consumer Price Index (CPI) for the March quarter has shown growth in pharmaceutical prices…

Asia-PacificAustraliaPharmaceuticalPoliticsPricing

Health care M&A activity in 1st-qtr 2014 softens compared with 4th-qtr 2013; report

23-04-2014

Health care merger and acquisition activity was a little soft in the first quarter of 2014. Deal volume…

Mergers & AcquisitionsPharmaceutical

Number of clinical trials in Russia declined in 2013

23-04-2014

The number of clinical trials taking place in Russia in 2013 amounted 791, which is 13.6% lower than…

Eastern EuropePharmaceuticalResearchRussia

Lupin appoints Theresa Stevens as Chief Corporate Development Officer

Lupin appoints Theresa Stevens as Chief Corporate Development Officer

23-04-2014

Pharma major Lupin has announced the appointment of Theresa Stevens as Chief Corporate Development Officer…

BoardroomLupinPharmaceuticalUSA

UK’s NICE rejects use of Roche’s Kadcyla for breast cancer on NHS

23-04-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued preliminary…

KadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

Gilead 1st-qtr 2014 sales nearly double, fuelled by Sovaldi, as net income rockets

23-04-2014

US antivirals major Gilead Sciences posted first-quarter 2014 results after markets closed yesterday,…

Anti-viralsBiotechnologyFinancialGilead SciencesSovaldi

Valeant joins with hedge fund in $45.6 billion unsolicited bid for Allergan

22-04-2014

Canada’s Valeant Pharmaceuticals International, never shy to go for hostile takeover moves, says it…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Lilly's Cyramza first FDA-approved drug for advanced gastric cancer after prior chemo

22-04-2014

The US Food and Drug Administration has approved pharma major Eli Lilly’s Cyramza (ramucirumab) as…

CyramzaEli LillyNorth AmericaOncologyPharmaceuticalRegulationUSA

1 to 25 of 7389 results

Back to top